TR200201503T2 - Heterosiklik türevler. - Google Patents
Heterosiklik türevler.Info
- Publication number
- TR200201503T2 TR200201503T2 TR2002/01503T TR200201503T TR200201503T2 TR 200201503 T2 TR200201503 T2 TR 200201503T2 TR 2002/01503 T TR2002/01503 T TR 2002/01503T TR 200201503 T TR200201503 T TR 200201503T TR 200201503 T2 TR200201503 T2 TR 200201503T2
- Authority
- TR
- Turkey
- Prior art keywords
- heterocyclic derivatives
- antagonize
- enantiomer
- pyrrolidinyl
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Bu bulus,7-kloro-4(2-okso-1-fenil-3-pirrolidinilden)-1,2,3,4 tetrahidro-2- kuinolin karboksilik asit A enantiomerinin yeni bir tuzu veya bir solvatiyla, hazirlanma prosesleriyle, bunlari içeren farmasötik terkiplerle ve terapide, özellikle NMDA reseptör kompleksi üzerinde uyarici amino asitlerin etkilerini antagonize etmek üzere bir ilaç olarak kullanimiyla ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9929037.1A GB9929037D0 (en) | 1999-12-08 | 1999-12-08 | Heterocyclic derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200201503T2 true TR200201503T2 (tr) | 2002-10-21 |
Family
ID=10865952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2002/01503T TR200201503T2 (tr) | 1999-12-08 | 2000-12-07 | Heterosiklik türevler. |
Country Status (30)
Country | Link |
---|---|
US (2) | US6713491B2 (tr) |
EP (1) | EP1237886B1 (tr) |
JP (1) | JP4311901B2 (tr) |
KR (1) | KR100788579B1 (tr) |
CN (1) | CN1325488C (tr) |
AR (1) | AR030923A1 (tr) |
AT (1) | ATE323691T1 (tr) |
AU (1) | AU769232B2 (tr) |
BR (1) | BR0016235A (tr) |
CA (1) | CA2393303C (tr) |
CO (1) | CO5251474A1 (tr) |
CY (1) | CY1106105T1 (tr) |
CZ (1) | CZ301052B6 (tr) |
DE (1) | DE60027461T2 (tr) |
DK (1) | DK1237886T3 (tr) |
ES (1) | ES2257343T3 (tr) |
GB (1) | GB9929037D0 (tr) |
HK (1) | HK1047436B (tr) |
HU (1) | HUP0203650A3 (tr) |
IL (2) | IL150010A0 (tr) |
MX (1) | MXPA02005802A (tr) |
MY (1) | MY129892A (tr) |
NO (1) | NO323263B1 (tr) |
PL (1) | PL356713A1 (tr) |
PT (1) | PT1237886E (tr) |
TN (1) | TNSN00240A1 (tr) |
TR (1) | TR200201503T2 (tr) |
TW (1) | TW524804B (tr) |
WO (1) | WO2001042238A1 (tr) |
ZA (1) | ZA200204492B (tr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096785A1 (ja) * | 2003-04-25 | 2004-11-11 | Nippon Chemiphar Co., Ltd. | (2s,3s)-3-[[(1s)-1-イソブトキシメチル-3-メチルブチル]カルバモイル]オキシラン-2-カルボン酸の塩 |
GB0327912D0 (en) * | 2003-12-02 | 2004-01-07 | Glaxo Group Ltd | Medicament |
US7576216B2 (en) | 2004-07-30 | 2009-08-18 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
PT3056492T (pt) | 2004-10-08 | 2021-12-27 | Abbvie Inc | Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) |
EP1868581B1 (en) * | 2005-04-11 | 2012-03-14 | Abbott Laboratories | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
ES2574262T3 (es) * | 2011-10-25 | 2016-06-16 | Janssen Pharmaceutica, N.V. | Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
US6413959B1 (en) * | 1995-04-14 | 2002-07-02 | Boehringer Ingelheim Kg | Method of treating depression with arylglycinamide derivatives |
AU708148B2 (en) | 1995-09-29 | 1999-07-29 | Glaxo Wellcome S.P.A. | Tetrahydroquinolines as NMDA antagonists |
GB9617305D0 (en) | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
-
1999
- 1999-12-08 GB GBGB9929037.1A patent/GB9929037D0/en not_active Ceased
-
2000
- 2000-07-12 US US10/148,434 patent/US6713491B2/en not_active Expired - Fee Related
- 2000-12-06 MY MYPI20005714A patent/MY129892A/en unknown
- 2000-12-07 WO PCT/EP2000/012335 patent/WO2001042238A1/en active IP Right Grant
- 2000-12-07 IL IL15001000A patent/IL150010A0/xx unknown
- 2000-12-07 DK DK00983240T patent/DK1237886T3/da active
- 2000-12-07 CO CO00093651A patent/CO5251474A1/es not_active Application Discontinuation
- 2000-12-07 EP EP00983240A patent/EP1237886B1/en not_active Expired - Lifetime
- 2000-12-07 AU AU20060/01A patent/AU769232B2/en not_active Ceased
- 2000-12-07 TR TR2002/01503T patent/TR200201503T2/tr unknown
- 2000-12-07 KR KR1020027007260A patent/KR100788579B1/ko not_active IP Right Cessation
- 2000-12-07 BR BR0016235-3A patent/BR0016235A/pt not_active Application Discontinuation
- 2000-12-07 CN CNB00816875XA patent/CN1325488C/zh not_active Expired - Fee Related
- 2000-12-07 AR ARP000106511A patent/AR030923A1/es unknown
- 2000-12-07 PL PL00356713A patent/PL356713A1/xx not_active Application Discontinuation
- 2000-12-07 TW TW089126096A patent/TW524804B/zh not_active IP Right Cessation
- 2000-12-07 CA CA002393303A patent/CA2393303C/en not_active Expired - Fee Related
- 2000-12-07 DE DE60027461T patent/DE60027461T2/de not_active Expired - Lifetime
- 2000-12-07 CZ CZ20021981A patent/CZ301052B6/cs not_active IP Right Cessation
- 2000-12-07 HU HU0203650A patent/HUP0203650A3/hu unknown
- 2000-12-07 AT AT00983240T patent/ATE323691T1/de active
- 2000-12-07 JP JP2001543537A patent/JP4311901B2/ja not_active Expired - Fee Related
- 2000-12-07 ES ES00983240T patent/ES2257343T3/es not_active Expired - Lifetime
- 2000-12-07 MX MXPA02005802A patent/MXPA02005802A/es active IP Right Grant
- 2000-12-07 PT PT00983240T patent/PT1237886E/pt unknown
- 2000-12-08 TN TNTNSN00240A patent/TNSN00240A1/en unknown
-
2002
- 2002-06-03 IL IL150010A patent/IL150010A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204492A patent/ZA200204492B/xx unknown
- 2002-06-06 NO NO20022682A patent/NO323263B1/no not_active IP Right Cessation
- 2002-12-14 HK HK02109085.5A patent/HK1047436B/zh not_active IP Right Cessation
-
2004
- 2004-02-10 US US10/775,709 patent/US6943176B2/en not_active Expired - Fee Related
-
2006
- 2006-06-26 CY CY20061100855T patent/CY1106105T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315547A (pt) | Derivados de quinolina como antagonistas de crth2 | |
DE50011582D1 (de) | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften | |
ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
AP1760A (en) | Platinum derivative pharmaceutical formulations. | |
DE69922676D1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden | |
SE9904505D0 (sv) | Novel compounds | |
EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
BR0016543A (pt) | Novos derivados de piperidina e piperazina | |
RS103903A (en) | Piperidine derivatives as nmda receptor antagonists | |
PT1086124E (pt) | Ciclosporinas novas | |
ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
TR200002969T2 (tr) | Farmasötik bileşim. | |
TR200000737T2 (tr) | İkame edilmiş kroman türevleri. | |
EP0337136A3 (en) | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | |
TR200201503T2 (tr) | Heterosiklik türevler. | |
EP0974352A4 (en) | SUBSTANCES FOR INHIBITING PTERYGIUM EDUCATION AND ITS POSTOPERATIVE RECURRENCE | |
MD553G2 (ro) | Derivaţi noi ai pirazolopirimidinelor, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice care le conţin | |
MXPA04003297A (es) | Derivados novedosos de benzotiacina su preparacion y uso. | |
HUP0000307A2 (hu) | Y Neuropeptid antagonisták és ezeket tartalmazó gyógyászati készítmények | |
SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
MX9600165A (es) | 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen. |